Search results for: 'Preferred Destination for Early Phase Clinical Trials'

The global clinical diagnostics market is poised for strong growth as stakeholders shift focus toward high-growth segments such as precision medicine, decentralized diagnostics, software-driven solutions, and product expansion. Companies continue to adopt LIMS and other digital platforms while emerging opportunities in the POCT sector further drive...

The global clinical diagnostics market is poised for strong growth, driven by increased adoption of advanced diagnostics technologies, greater investment in laboratories, and improved access to molecular and immunodiagnostic testing facilities. In 2025, the industry continued its transformation, establishing testing systems as intelligent systems...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...

The clinical laboratory testing industry will continue to experience growth in testing volumes due to the aging of the US population, patient awareness of the benefits of laboratory testing, test cost reductions, the development of advanced and specialized tests for disease detection and management, the growing awareness of early detection and prev...

The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as ...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

The global POCT market is rapidly evolving from standalone rapid diagnostics to connected, AI-enabled clinical intelligence ecosystems that support decentralized healthcare delivery. Growth is driven by the increasing demand for faster clinical decision-making, early disease detection, personalized treatment, and expanded access to testing across h...

The molecular diagnostics industry is undergoing consolidation, requiring capital investment and faster regulatory pathways to accelerate clinical adoption. Major diagnostics and life sciences companies are acquiring proprietary testing platforms to strengthen positions in precision oncology and blood-based diagnostics. AI-enabled genomic workflow ...